CARMUSTINE

Peak

carmustine

NDAINTRAVENOUSPOWDER
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

understood. While carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. The metabolites may contribute to antitumor activity and toxicities of…

Clinical Trials (4)

NCT05083754Phase 1Recruiting

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Started Aug 2022
50 enrolled
Glioblastoma Multiforme
NCT00984438Phase 1/2Withdrawn

Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme

Started Jun 2009
0
Glioblastoma Multiforme
NCT00795665Phase 2Completed

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

Started Jun 2008
7 enrolled
Glioma
NCT00068952Phase 3Completed

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Started Aug 2003
118 enrolled
Glioblastoma